Loading provider…
Loading provider…
Hematology & Oncology Physician in Lakewood, CA
NPI: 1982989836Primary Practice Location
Lakewood Eye Physicians
3300 E South St, Lakewood, California, 90805
HQ Phone
Get MD Omkar's Phone NumberMobile
Get MD Omkar's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2011 - 2025
CA State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Olive View/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
2013 - 2016
Scripps Clinic/Scripps Green Hospital
scripps.org
Residency • Internal Medicine
2010 - 2013
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 116 | 232 |
| 2 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 60 | 108 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 40 | 46 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 35 | 104 |
| 5 | 36591Collection of blood specimen from a completely implantable venous access device | 28 | 89 |
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
Authors: Carla Falkson, Dennis Slamon, John Timmerman, Vincente Valero, David Betting, Adam Brufsky, Sara Hurvitz
Publication Date: 2012-06
A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor.
Authors: Mufti, Muhammad, Marathe, Omkar
Journal: J Hematol
Publication Date: 2018-05-10
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid t...
Authors: J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung
Lead Sponsor: Cardurion Pharmaceuticals, Inc.
Collaborators: Imara, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: IMR-687